{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:04:07Z","timestamp":1793412247564,"version":"4.5.0"},"reference-count":9,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chen and colleagues report excellent durability of response at 2 years for patients responding to pembrolizumab for relapsed Hodgkin lymphoma.<\/jats:p>","DOI":"10.1182\/blood.2019000324","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T22:25:13Z","timestamp":1565735113000},"page":"1144-1153","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":309,"title":["Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087"],"prefix":"10.1182","volume":"134","author":[{"given":"Robert","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cSer\u00e0gnoli\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun Ju","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jewish General Hospital, Montreal, QC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Hopital Saint Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"name":"Department of Drug Development and Hematology, Institut Gustave Roussy, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Molin","sequence":"additional","affiliation":[{"name":"Section of Experimental and Clinical Oncology, Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, General Hospital of Athens, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cologne and University Hospital of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Shipp","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Lin","sequence":"additional","affiliation":[{"name":"Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhee","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Nahar","sequence":"additional","affiliation":[{"name":"Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Balakumaran","sequence":"additional","affiliation":[{"name":"Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig H.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"issue":"9","key":"2019111523521154800_B3","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"2019111523521154800_B4","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"31","key":"2019111523521154800_B5","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111523521154800_B6","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"2019111523521154800_B1","unstructured":"National Comprehensive Cancer Network\n          . NCCN clinical practice guidelines in oncology (NCCN guidelines): Hodgkin lymphoma (Version 3.). 16 April 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf. Accessed 20 February 2019."},{"key":"2019111523521154800_B7","year":"2018"},{"key":"2019111523521154800_B8","year":"2019"},{"issue":"5","key":"2019111523521154800_B9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111523521154800_B10","unstructured":"Merck Sharp & Dohme Corp\n          . Study of pembrolizumab (MK-3475) vs. brentuximab vedotin in participants with relapsed or refractory classical Hodgkin lymphoma (MK-3475-204\/KEYNOTE-204). Updated 31 July 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02684292. Accessed 20 February 2019."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/14\/1144\/1223052\/bloodbld2019000324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/14\/1144\/1223052\/bloodbld2019000324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:30:09Z","timestamp":1573864209000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/14\/1144\/374896\/Pembrolizumab-in-relapsed-or-refractory-Hodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":9,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2019,8,13]]},"published-print":{"date-parts":[[2019,10,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000324","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]}}}